Australia's CSL falls; Macquarie cuts PT, lowers rating on weaker outlook

Csl

15/12/2025 01:56

Updates

** CSL CSL.AX falls as much as 2% to A$180.25; marks largest intraday pct loss since December 5

** Macquarie cuts PT to A$188 from A$275, downgrades to "neutral" from "outperform"

** Trims EPS estimates by 4%, 5% and 5% for FY26, FY27 and FY28, respectively, reflecting downgraded guidance due to softer performance at Seqirus, among others

**  Sees risk to co's FY26 guidance with H2 reliant on containing China's albumin impacts

** Estimates 25% of CSL Behring's immunoglobulin share in Chronic Inflammatory Demyelinating Polyneuropathy at risk, which could result in 4% EPS impact by FY33

** Stock rated "buy" on avg; median PT is A$237, per data compiled by LSEG

** CSL slips 35.8% YTD

 (Reporting by Sneha Kumar and Nikita Maria Jino in Bengaluru)

 ((Sneha.kumar@thomsonreuters.com;))